{"organizations": [], "uuid": "f0ee96b9a7427457e2ac96405672f448826a8ca5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alnylam-reaches-settlement-agreeme/brief-alnylam-reaches-settlement-agreement-with-dicerna-pharmaceuticals-idUSFWN1RX0U6", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-20T19:49:00.000+03:00", "replies_count": 0, "uuid": "f0ee96b9a7427457e2ac96405672f448826a8ca5"}, "author": "", "url": "https://www.reuters.com/article/brief-alnylam-reaches-settlement-agreeme/brief-alnylam-reaches-settlement-agreement-with-dicerna-pharmaceuticals-idUSFWN1RX0U6", "ord_in_thread": 0, "title": "BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals", "locations": [], "entities": {"persons": [{"name": "dicerna pha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "alnylam pharmaceuticals", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20, 2018 / 4:50 PM / in 30 minutes BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals Reuters Staff \nApril 20 (Reuters) - Alnylam Pharmaceuticals Inc: \n* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION \n* ALNYLAM PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, DICERNA WILL PAY $25 MILLION COMPRISED OF CASH AND STOCK TO ALNYLAM \n* ALNYLAM PHARMACEUTICALS INC - SETTLEMENT DOES NOT INCLUDE ANY LICENSE TO ALNYLAM’S GALNAC CONJUGATE INTELLECTUAL PROPERTY \n* ALNYLAM - AS PER SETTLEMENT, DICERNA WILL BE RESTRICTED IN ITS DEVELOPMENT RELATING TO OLIGONUCLEOTIDE-BASED THERAPEUTICS FOR A DEFINED SET OF CO’S TARGETS \n* ALNYLAM PHARMACEUTICALS - ALL OTHER SETTLEMENT TERMS ARE CONFIDENTIAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-20T19:49:00.000+03:00", "crawled": "2018-04-20T20:29:28.018+03:00", "highlightTitle": ""}